Akoya Biosciences, Inc.

Symbol: AKYA




Market price today

  • -3.4730

    P/E Ratio

  • 0.2778

    PEG Ratio

  • 221.22M

    MRK Cap

  • 0.00%

    DIV Yield

Akoya Biosciences, Inc. (AKYA) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO:Mr. Brian McKelligon
Full-time employees:330
Address:100 Campus Drive

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

General Outlook

When we look at how much money they make before expenses, they keep 0.563% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.588%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.655%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.351% return, is a testament to Akoya Biosciences, Inc.'s adeptness in optimizing resource deployment. Akoya Biosciences, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.102%. Furthermore, the proficiency of Akoya Biosciences, Inc. in capital utilization is underscored by a remarkable -0.392% return on capital employed.

Stock Prices

Akoya Biosciences, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $4.1, while its low point bottomed out at $3.83. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Akoya Biosciences, Inc.'s stock market.

Liquidity Ratios

Analyzing AKYA liquidity ratios reveals its financial health of the firm. The current ratio of 344.57% gauges short-term asset coverage for liabilities. The quick ratio (283.26%) assesses immediate liquidity, while the cash ratio (235.18%) indicates cash reserves.

Current Ratio344.57%
Quick Ratio283.26%
Cash Ratio235.18%

Profitability Ratios

AKYA profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -65.49% underscores its earnings before tax deductions. The effective tax rate stands at -0.02%, revealing its tax efficiency. The net income per EBT, 100.06%, and the EBT per EBIT, 111.37%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -58.80%, we grasp its operational profitability.

Pretax Profit Margin-65.49%
Effective Tax Rate-0.02%
Net Income per EBT100.06%
EBT per EBIT111.37%
EBIT per Revenue-58.80%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 3.45, it details the span from stock purchase to revenue. The 3 days it takes to settle debts showcases its creditor relations. Meanwhile, a 2 cash conversion cycle and 568.63% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding283
Days of Inventory Outstanding155
Operating Cycle218.81
Days of Payables Outstanding102
Cash Conversion Cycle117
Receivables Turnover5.69
Payables Turnover3.58
Inventory Turnover2.36
Fixed Asset Turnover4.68
Asset Turnover0.54

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.04, and free cash flow per share, -1.11, depict cash generation on a per-share basis. The cash per share value, 1.69, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.53, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-1.04
Free Cash Flow per Share-1.11
Cash per Share1.69
Operating Cash Flow Sales Ratio-0.53
Free Cash Flow to Operating Cash Flow Ratio1.07
Cash Flow Coverage Ratio-0.65
Short Term Coverage Ratio-14.75
Capital Expenditure Coverage Ratio-13.92
Dividend Paid and Capex Coverage Ratio-13.92

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 43.63%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.46, we discern the balance between debt and equity financing. The long-term debt to capitalization, 58.33%, and total debt to capitalization, 59.41%, ratios shed light on its capital structure. An interest coverage of -13.27 indicates its ability to manage interest expenses.

Debt Ratio43.63%
Debt Equity Ratio1.46
Long Term Debt to Capitalization58.33%
Total Debt to Capitalization59.41%
Interest Coverage-13.27
Cash Flow to Debt Ratio-0.65
Company Equity Multiplier3.35

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 2.17, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.43, reflects the portion of profit attributed to each share. The book value per share, 1.21, represents the net asset value distributed per share, while the tangible book value per share, 0.41, excludes intangible assets.

Revenue Per Share2.17
Net Income Per Share-1.43
Book Value Per Share1.21
Tangible Book Value Per Share0.41
Shareholders Equity Per Share1.21
Interest Debt Per Share1.97
Capex Per Share-0.08

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 29.09%, indicates top-line expansion, while the gross profit growth, 11.17%, reveals profitability trends. EBIT growth, 15.37%, and operating income growth, 15.37%, offer insights into operational profitability progression. The net income growth, 10.36%, showcases bottom-line expansion, and the EPS growth, 23.53%, measures the growth in earnings per share.

Revenue Growth29.09%
Gross Profit Growth11.17%
EBIT Growth15.37%
Operating Income Growth15.37%
Net Income Growth10.36%
EPS Growth23.53%
EPS Diluted Growth23.53%
Weighted Average Shares Growth17.72%
Weighted Average Shares Diluted Growth17.72%
Operating Cash Flow Growth4.85%
Free Cash Flow Growth10.36%
10-Year Revenue Growth per Share91.08%
5-Year Revenue Growth per Share91.08%
3-Year Revenue Growth per Share90.15%
10-Year Operating CF Growth per Share-208.58%
5-Year Operating CF Growth per Share-208.58%
3-Year Operating CF Growth per Share-521.21%
10-Year Net Income Growth per Share-258.52%
5-Year Net Income Growth per Share-258.52%
3-Year Net Income Growth per Share-216.57%
10-Year Shareholders Equity Growth per Share248.90%
5-Year Shareholders Equity Growth per Share248.90%
3-Year Shareholders Equity Growth per Share141.81%
Receivables Growth74.67%
Inventory Growth23.41%
Asset Growth2.46%
Book Value per Share Growth-22.03%
Debt Growth13.09%
R&D Expense Growth-5.70%
SGA Expenses Growth3.42%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 219,421,701.6, captures the company's total value, considering both debt and equity. Income quality, 0.80, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 19.78%, indicates the value of non-physical assets, and capex to operating cash flow, 7.18%, measures reinvestment capability.

Enterprise Value219,421,701.6
Income Quality0.80
Research and Development to Revenue22.65%
Intangibles to Total Assets19.78%
Capex to Operating Cash Flow7.18%
Capex to Revenue-3.78%
Capex to Depreciation-41.09%
Stock-Based Compensation to Revenue10.80%
Graham Number6.23
Return on Tangible Assets-43.76%
Graham Net Net-0.49
Working Capital86,445,000
Tangible Asset Value18,096,000
Net Current Asset Value-4,809,000
Invested Capital1
Average Receivables13,361,500
Average Payables19,461,500
Average Inventory16,181,500
Days Sales Outstanding64
Days Payables Outstanding89
Days of Inventory On Hand135

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 4.09, and the price to book ratio, 4.09, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.29, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -4.06, and price to operating cash flows, -4.32, gauge market valuation against cash flow metrics.

Price Book Value Ratio4.09
Price to Book Ratio4.09
Price to Sales Ratio2.29
Price Cash Flow Ratio-4.32
Price Earnings to Growth Ratio0.28
Enterprise Value Multiple-4.35
Price Fair Value4.09
Price to Operating Cash Flow Ratio-4.32
Price to Free Cash Flows Ratio-4.06
Price to Tangible Book Ratio4.03
Enterprise Value to Sales2.27
Enterprise Value Over EBITDA-4.65
EV to Operating Cash Flow-4.31
Earnings Yield-29.20%
Free Cash Flow Yield-25.16%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Akoya Biosciences, Inc. (AKYA) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -3.473 in 2024.

What is the ticker symbol of Akoya Biosciences, Inc. stock?

The ticker symbol of Akoya Biosciences, Inc. stock is AKYA.

What is company IPO date?

IPO date of Akoya Biosciences, Inc. is 2021-04-16.

What is company current share price?

Current share price is 4.480 USD.

What is stock market cap today?

The market cap of stock today is 221223296.000.

What is PEG ratio in 2024?

The current 0.278 is 0.278 in 2024.

What is the number of employees in 2024?

In 2024 the company has 330.